Uppsala, Sweden May 9 2017. Biovica has received a new patent in China as well as patent extension for the company’s technology in the United States.
Both of the patents refer to Biovica’s method of measuring thymidine kinase activity on a real-time PCR platform. The Chinese patent is valid until 13 May 2031. The U.S. patent was previously approved but is now extended with 430 days, which means that patent is valid until July 16, 2032.
” It is important for Biovica that we can protect our unique technology. Hence, we’re are pleased that we now strengthen our patent protection in two of the largest and most important markets. These two patents enable us to offer our innovative methods to the benefit of cancer patients and payer for many years to come.” says Anders Rylander, CEO Biovica.
Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company’s DiviTum® assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality.
Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum® is CE-labeled and MPA-registered. Appointed Certified Adviser to the company is FNCA Sweden AB.
Read more: www.biovica.com